Anti-aging composition for middle-aged and elderly people

Abstract

The invention provides an anti-aging composition for middle-aged and elderly people. The anti-aging composition comprises B vitamins and beta-nicotinamide mononucleotide. In the invention, the weight ratio of the vitamin B to the beta-nicotinamide mononucleotide is (0.1-1): (10-200); the vitamin B is selected from folic acid substances and can also comprise vitamin B12. The composition is used for resisting aging and preventing senile dementia symptoms caused by aging.

Description

Technical Field

[0001] The invention relates to a composition for middle-aged and elderly people to resist aging and prevent symptoms of Alzheimer's disease caused by aging, belonging to the technical field of medicine. Background Art

[0002] Since 2020, my country's population aging has presented a new situation, mainly manifested in the following characteristics: the number of elderly people has grown rapidly. From 2001 to 2020, my country was in a stage of rapid aging. The average growth rate of the elderly population was much higher than the average annual growth rate of the total population. At this stage, my country's aging situation has entered a new acceleration stage (2021-2050). Secondly, the base of the elderly population is huge, and the aging trend of the population has created a huge economic burden, as well as a medical and health burden. Among them, the various health problems caused by aging are difficult to solve, especially the family burden caused by Alzheimer's disease is becoming more and more serious.

[0003] Alzheimer's disease is a neurodegenerative disease of the brain. It is difficult to find a treatment method because of its unknown cause. In recent years, although some drug clinical research trials have tried to find a solution, they have not achieved the expected results. More precisely, there is still no definite and effective solution for patients with symptoms of Alzheimer's disease.

[0004] β-Nicotinamide mononucleotide (NMN) is a precursor of coenzyme (NAD+) in the human body. The NAD+ content in the human body decreases with age, causing diseases such as Alzheimer's disease, cardiovascular and cerebrovascular diseases, and diabetes. Supplementing with NMN can increase the NAD+ content in the human body and play an anti-aging role. However, there are also reports that its effect on improving aging or Alzheimer's disease is not clear and is still very controversial.

[0005] B vitamins, especially folic acid and vitamin B12 supplementation, can reduce the level of homocysteine ​​in the body. High homocysteine ​​is a chemical in the blood that is associated with heart disease and dementia. Folic acid supplementation has an improvement in tests of memory level, cognitive speed, information processing ability and overall thinking ability.

[0006] Various previous studies have shown that Alzheimer's disease is more of a naturally occurring brain neurodegenerative disease that accompanies aging, and is a symptom caused by the process of body function decline. Therefore, it is particularly important to find a nutritional supplement program to prevent aging before Alzheimer's disease occurs, which has broad social benefits and public health significance. Summary of the invention

[0007] In response to the urgent need for medication for Alzheimer's disease complicated by aging, the present invention team proposed a composition containing B vitamins and β-nicotinamide mononucleotide.

[0008] To achieve the above object, the present invention adopts the following technical solutions:

[0009] A composition comprising:

[0010] (1) B vitamins,

[0011] (2) β-nicotinamide mononucleotide,

[0012] (3) Pharmaceutically acceptable excipients.

[0013] In the composition of the present invention, the weight ratio of the B vitamins to β-nicotinamide mononucleotide is 0.1-1:10-200.

[0014] The composition of the present invention contains 0.01 to 1 parts of B vitamins and 10 to 200 parts of β-nicotinamide mononucleotide by weight; preferably, it contains 0.2 to 0.8 parts of B vitamins and 100 to 150 parts of β-nicotinamide mononucleotide.

[0015] The composition of the present invention contains 0.01-1 mg of B vitamins and 10-200 mg of β-nicotinamide mononucleotide; preferably, contains 0.2-0.4 mg of B vitamins and 100-200 mg of β-nicotinamide mononucleotide.

[0016] The composition described in the present invention, wherein the B vitamins are folic acid substances, may also include vitamin B12. Further, the amount of folic acid substances is 0.001-1 mg, and the amount of vitamin B12 is 0.1-10 μg.

[0017] In the composition of the present invention, the folic acid substance is selected from one or more of synthetic folic acid, 5-methyltetrahydrofolate, folinic acid, folinic acid or active metabolites of folate and substances that can release / generate folic acid in vivo.

[0018] In the composition of the present invention, vitamin B12 is methylcobalamin, 5'-deoxyadenosylcobalamin, hydroxocobalamin, cyanocobalamin or other substances that can release / generate cobalamin in vivo.

[0019] The composition described in the present invention is characterized in that the composition can be prepared into oral dosage forms such as tablets, pills, granules, oral liquids, capsules, powders and granules.

[0020] The composition of the present invention is used in the preparation of anti-aging products.

[0021] The composition of the present invention is used in the preparation of a drug for delaying aging and dementia in middle-aged and elderly people.

[0022] The present invention provides a composition containing B vitamins and β-nicotinamide mononucleotide, and more specifically, the present invention provides a composition of folic acid, vitamin B12 and β-nicotinamide mononucleotide with a specific dosage ratio. The exploratory experiments of this team have proved that it has a clear anti-aging effect and has a definite and significant synergistic effect of delaying aging-associated Alzheimer's disease. DETAILED DESCRIPTION

[0023] The specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0024] Example 1: Effect of the composition of the present invention on the aging process of middle-aged and elderly rats

[0025] In order to verify the efficacy of the present invention in preventing and improving symptoms of Alzheimer's disease caused by aging, as well as the preferred dosage of the composition, we designed a Morris water maze test to detect the learning and memory functions of D-galactose aged mice through behavioral testing.

[0026] Experimental animals and groups: SPF grade Kunming (SD) rats, half male and half female, weighing 250±50g, were raised in an environment with a room temperature of 18-28℃ and a relative humidity of 40%-70%, with free access to water. After 1 week of adaptive feeding with ordinary feed, they were randomly divided into the groups shown in Table 1 below, with 10 rats in each group. Each group of mice was fed continuously for 7 days according to the groups in Table 1, and the model was established on the 8th day and the Morris water maze behavioral test was performed.

[0027] During the experiment, mice in the model group and the test group were subcutaneously injected with D-galactose 120 mg / kg on the back, once a day, for 45 consecutive days to create an aging model. The control group was injected with an equal amount of normal saline, and then the following tests were performed. From the beginning of modeling to the end of the experiment, rats in each group were gavaged with the corresponding composition according to the table below, and the gavage volume was calculated based on 10 ml / kg.

[0028] Morris water maze behavioral test: ① Positioning navigation experiment: used to detect the spatial learning ability of mice. The experiment lasted for 6 days. Each quadrant was tested once every afternoon. Each test lasted for 60 seconds. The time it took to find the platform within 60 seconds (escape latency) was recorded. If the mouse did not find the platform within 60 seconds, the experimenter would pull it to the platform by hand and stay for 10 seconds. The escape latency was recorded as 60 seconds. There was a 20-second interval between the two experiments. The latency of the mouse was recorded. ② Spatial exploration experiment: used to detect the spatial memory ability of mice. On the 7th day of the above experiment, the platform was removed, and the mouse entered the water from the quadrant opposite to the quadrant where the platform was located facing the pool wall, so that the mouse could find the platform in memory without a platform. The time it stayed in the target quadrant and the number of times it crossed the original platform within 60 seconds were recorded.

[0029] Experimental results: In order to verify the scientific nature of the pharmaceutical composition provided by the present invention, and to illustrate that the two components of the pharmaceutical composition are reasonably matched and can play a synergistic role in combination, rather than simply superimposing pharmacological effects, the Jin Zhengjun Q value method is introduced for analysis. The Jin Zhengjun Q value method is also known as the probability addition method. According to the pharmacological effects of the two drugs in combination and the pharmacological effects of the two drugs alone in the dose-effect curve area, the following calculation formula is used to calculate: Q = E A+B / (E A +E B -E A *E B ), where the numerator represents the "measured combined effect" and the denominator represents the "expected combined effect". (In order to analyze the pharmacological effects of components and combinations, their pharmacological effects are converted into effects that can intuitively reflect the strength of the pharmacological effects. The calculation formula is: E i =1-P i / P 模型组 , P i is the pharmacological index of each component, P 模型组 is the pharmacological index of the model group), Q is the ratio of the two: when Q is less than 0.85, the combination of the two drugs is considered to be antagonistic; when it is less than 1.15 and greater than 0.85, it is considered to be additive; when it is greater than 1.15, it is considered to be synergistic.

[0030] As shown in the experimental results in Table 1, in the positioning navigation experiment, as the training progressed, on days 2-6, the latency of the mice in the model group was significantly greater than that in the control group, indicating that after subcutaneous injection of D-galactose, the learning ability of the mice was significantly reduced, with significant statistical differences (P < 0.05 or P < 0.01). Compared with the model group, there was no significant change in the low-dose group of NMNM or folic acid, and the average escape latency of the high-dose group was significantly shortened from the 4th day, with significant statistical changes (P < 0.05), and the latency of the mice in the combination of NMN+folic acid, whether in the low-dose group or the high-dose group, was significantly shorter than that of the group taking NMN or folic acid alone at the corresponding dose, especially the high-dose group. From the experimental results, it can be seen that NMN+folic acid has a significant synergistic effect on improving learning and memory function in aging mice (Q values ​​of the low-dose group of NMN+folic acid and the high-dose group of NMN+folic acid on the 7th day were ≥ 1.15).

[0031] Table 1: Average escape latency (s) of mice in each group in the water maze directional navigation test

[0032]

[0033]

[0034] Note: Compared with the control group, *P<0.05, **P<0.01; compared with the model group, #P<0.05, ##P<0.01.

[0035] As shown in the experimental results in Table 2, in the spatial exploration experiment, the average number of times the model group mice crossed the platform and the target quadrant residence time were significantly lower than those in the control group (P<0.05). Compared with the model group, there was no significant change in the low-dose group of NMN or folic acid; the average number of times the high-dose group mice crossed the platform increased significantly, and the target quadrant residence time was significantly prolonged, with significant statistical differences (P<0.05); and the NMN+folic acid combination, whether low-dose group or high-dose group, compared with the corresponding dose of NMN or folic acid alone, the average number of times the platform was crossed was significantly increased, and the target quadrant residence time was significantly prolonged, especially the high-dose combination. From the experimental results, it can be seen that NMN+folic acid has a significant synergistic effect on improving the spatial exploration function in aging mice (Q values ​​are ≥1.15).

[0036] Table 2: Water maze spatial exploration experiment results of mice in each group

[0037]

[0038] Note: Compared with the control group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.

Claims

1. A composition for anti-aging of middle-aged and elderly people, comprising: (1) B vitamins, (2) β-nicotinamide mononucleotide, (3) Pharmaceutically acceptable excipients.

2. The composition according to claim 1, characterized in that The weight ratio of the B vitamins to β-nicotinamide mononucleotide is 0.1-1:10-200.

3. The composition according to claim 1, characterized in that By weight, it contains 0.01 to 1 parts of B vitamins and 10 to 200 parts of β-nicotinamide mononucleotide; preferably, it contains 0.2 to 0.8 parts of B vitamins and 100 to 150 parts of β-nicotinamide mononucleotide.

4. The composition according to claim 1, characterized in that The dosage of B vitamins is 0.01-1 mg, and the dosage of β-nicotinamide mononucleotide is 10-200 mg; preferably, the dosage of B vitamins is 0.2-0.4 mg, and the dosage of β-nicotinamide mononucleotide is 100-200 mg.

5. The composition according to claim 1, characterized in that The B vitamins include folic acid substances and may also include vitamin B12; further, the amount of folic acid substances is 0.001-1 mg, and the amount of vitamin B12 is 0.1-10 μg.

6. The composition according to claim 5, characterized in that The folic acid substance is selected from one or more of the active metabolites of synthetic folic acid, 5-methyltetrahydrofolate, formyltetrahydrofolate, folinic acid or folate and substances that can release / generate folic acid in vivo.

7. The composition according to claim 5, characterized in that The vitamin B12 is methylcobalamin, 5'-deoxyadenosylcobalamin, hydroxocobalamin, cyanocobalamin or other substances that can release / generate cobalamin in the body.

8. The composition according to claim 1, characterized in that The composition can be prepared into oral dosage forms such as tablets, pills, granules, oral liquids, capsules, powders and granules.

9. Use of the composition according to any one of claims 1 to 8 in the preparation of anti-aging products.

10. Use of the composition according to any one of claims 1 to 8 in the preparation of a drug for delaying aging and dementia in the elderly.

Images